Bod Science Announces Delay in Appendix 4D Lodgement
Bod Science (ASX:BOD) said its appendix 4D, or half-year report, for the six months ended Dec. 31, 2023, will be delayed anew following a rejection by the the Australian Securities and Investments Com
BOD Science Signs Supply Agreement in Medicinal Cannabis With Green Farmers
BOD Science (ASX:BOD) signed a supply agreement with licensed cultivator, importer, and genetic holder of medicinal cannabis, Green Farmers, according to a Wednesday release. BOD Science will supply a
Bod Science Receives AU$1.6 Million R&D Tax Refund; Shares Rise 8%
Bod Science (ASX:BOD) received a more than AU$1.6 million of research and development tax rebate for fiscal 2023. The rebate fully covers the outstanding AU$1.2 million loan payable to Radium Capital,
Bod Expects to Receive Funds From Antah Soon
Bod Science (ASX:BOD) provided an update on its capital raising program, saying it did not secure the AU$440,000 on Nov. 20, because of a delay in the receipt of funds from investor Antah Healthcare G
Bod Science Delays Settlement of Tranche 1 of AU$2.1 Million Placement
The settlement of the first tranche of Bod Science's (ASX:BOD) placement to raise AU$2.1 million has been delayed to Nov. 20. The shares were originally expected to be issued on Monday, Nov. 14, the m
Bod Science Raises AU$2.1 Million Via Share Placement; Shares Fall 43%
Bod Science (ASX:BOD) raised AU$2.1 million via a two-tranche placement priced at AU$0.03 per share. Proceeds will be used to build the cannabis drug developer's inventory, manufacture products, for w
Australian Shares Retreat as Monthly CPI Indicator Rises
Australian shares retreated on Wednesday amid concerns of a longer monetary tightening period as the country's monthly Consumer Price Index indicator rose 5.2% in the 12 months to August. The S&P/ASX
Bod Science Validates Greater Bioavailability of Drug Delivery Technology; Shares Rally 12%
Bod Science (ASX:BOD) validated the greater bioavailability of its Aqua Phase drug delivery technology following the results of a recent pharmacokinetic study, the medical cannabis firm said on Wednes
Express News | Bod Science Completes Acquisition of Drug Delivery Technology; Shares Up 3%
Bod Science Validates Bioavailability of Aqua Phase Technology
Bod Science (ASX:BOD) validated a bioavailability capability of its Aqua Phase drug delivery technology following results from a recent pharmacokinetic study, the medical cannabis firm said on Tuesday
Bod Science Signs Letter of Intent to Sell Medical Cannabis Products in Malaysia
Bod Science (ASX:BOD) signed a non-binding letter of intent with investment holding firm Antah Group to develop, market, and sell medical cannabis products in Malaysia, according to a Wednesday report.
TMH Spotlight: Bod Science (ASX:BOD) Introduces Cannabis in Malaysian Health Care, Aurumin (ASX:AUN) Poised to Drill at Mt Palmer
Bod Science (ASX:BOD) Expands Cannabis Products Into Malaysian Market
Bod Science Limited (ASX:BOD) Insider Purchases A$16,411.44 in Stock
Bod Science Limited (ASX:BOD – Get Rating) insider David Baker purchased 273,524 shares of the business's stock in a transaction dated Tuesday, March 7th. The shares were purchased at an average cost
Bod Science (ASX:BOD) Establishes R&D Funding Facility With Radium Capital
Non-Executive Chairman David Baker Just Bought A Handful Of Shares In Bod Australia Limited (ASX:BOD)
No Data